Novavax, Inc. (NVAX) Initiates First Phase 1 Clinical Trial of Its A(H7N9) Influenza Vaccine Candidate
7/8/2013 9:59:35 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ROCKVILLE, Md., July 8, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that enrollment has begun in a Phase 1 clinical trial of its monovalent virus-like particle (VLP) vaccine candidate for the prevention of disease due to A/Anhui/1/13-like A(H7N9) avian influenza viruses (A(H7N9) vaccine).
Help employers find you! Check out all the jobs and post your resume.
comments powered by